Titre : Dermatofibrosarcome

Dermatofibrosarcome : Questions médicales fréquentes

Termes MeSH sélectionnés :

Immunization Programs
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Dermatofibrosarcome : Questions médicales les plus fréquentes", "headline": "Dermatofibrosarcome : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Dermatofibrosarcome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-05", "dateModified": "2025-03-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Dermatofibrosarcome" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Fibrosarcome", "url": "https://questionsmedicales.fr/mesh/D005354", "about": { "@type": "MedicalCondition", "name": "Fibrosarcome", "code": { "@type": "MedicalCode", "code": "D005354", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.450.795.350" } } }, "about": { "@type": "MedicalCondition", "name": "Dermatofibrosarcome", "alternateName": "Dermatofibrosarcoma", "code": { "@type": "MedicalCode", "code": "D018223", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Aseel Sleiwah", "url": "https://questionsmedicales.fr/author/Aseel%20Sleiwah", "affiliation": { "@type": "Organization", "name": "Department of Plastic and Reconstructive Surgery, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK. aseelnajeeb@yahoo.com." } }, { "@type": "Person", "name": "Yoshinao Oda", "url": "https://questionsmedicales.fr/author/Yoshinao%20Oda", "affiliation": { "@type": "Organization", "name": "Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. oda.yoshinao.389@m.kyushu-u.ac.jp." } }, { "@type": "Person", "name": "Katherine E Mallett", "url": "https://questionsmedicales.fr/author/Katherine%20E%20Mallett", "affiliation": { "@type": "Organization", "name": "Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A." } }, { "@type": "Person", "name": "Ryan M Claxton", "url": "https://questionsmedicales.fr/author/Ryan%20M%20Claxton", "affiliation": { "@type": "Organization", "name": "Alix School of Medicine, Mayo Clinic, Rochester, MN, U.S.A." } }, { "@type": "Person", "name": "Peter C Ferguson", "url": "https://questionsmedicales.fr/author/Peter%20C%20Ferguson", "affiliation": { "@type": "Organization", "name": "Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Driving more WHO-recommended vaccines in the National Immunization Program: Issues and challenges in China.", "datePublished": "2023-04-26", "url": "https://questionsmedicales.fr/article/37099400", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/21645515.2023.2194190" } }, { "@type": "ScholarlyArticle", "name": "Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36933984", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.vaccine.2023.03.007" } }, { "@type": "ScholarlyArticle", "name": "A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.", "datePublished": "2022-06-15", "url": "https://questionsmedicales.fr/article/35703731", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/21645515.2022.2079305" } }, { "@type": "ScholarlyArticle", "name": "The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon's Expanded program on Immunization.", "datePublished": "2023-11-13", "url": "https://questionsmedicales.fr/article/37957695", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12960-023-00869-7" } }, { "@type": "ScholarlyArticle", "name": "Analyzing the usage of theories of change for routine immunization programs -- a review of impact evaluations from LMICs.", "datePublished": "2024-09-09", "url": "https://questionsmedicales.fr/article/39252041", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41043-024-00615-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://questionsmedicales.fr/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs par type histologique", "item": "https://questionsmedicales.fr/mesh/D009370" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs du tissu conjonctif et des tissus mous", "item": "https://questionsmedicales.fr/mesh/D018204" }, { "@type": "ListItem", "position": 5, "name": "Sarcomes", "item": "https://questionsmedicales.fr/mesh/D012509" }, { "@type": "ListItem", "position": 6, "name": "Fibrosarcome", "item": "https://questionsmedicales.fr/mesh/D005354" }, { "@type": "ListItem", "position": 7, "name": "Dermatofibrosarcome", "item": "https://questionsmedicales.fr/mesh/D018223" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Dermatofibrosarcome - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Dermatofibrosarcome", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Dermatofibrosarcome", "description": "Comment diagnostique-t-on un dermatofibrosarcome ?\nQuels examens complémentaires sont nécessaires ?\nQuels signes cliniques indiquent un dermatofibrosarcome ?\nLe dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?\nQuel rôle joue l'histopathologie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Immunization+Programs&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Dermatofibrosarcome", "description": "Quels sont les symptômes d'un dermatofibrosarcome ?\nLe dermatofibrosarcome provoque-t-il des douleurs ?\nPeut-on observer des changements de couleur sur la lésion ?\nLes démangeaisons sont-elles fréquentes ?\nLa lésion peut-elle saigner ?", "url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Immunization+Programs&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Dermatofibrosarcome", "description": "Peut-on prévenir le dermatofibrosarcome ?\nLes personnes à risque doivent-elles être surveillées ?\nL'exposition au soleil influence-t-elle le risque ?\nDes mesures de protection cutanée sont-elles recommandées ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?", "url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Immunization+Programs&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Dermatofibrosarcome", "description": "Quel est le traitement principal du dermatofibrosarcome ?\nLa radiothérapie est-elle utilisée ?\nDes traitements médicamenteux sont-ils disponibles ?\nQuelle est l'importance de la surveillance post-opératoire ?\nPeut-on traiter le dermatofibrosarcome par chimiothérapie ?", "url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Immunization+Programs&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Dermatofibrosarcome", "description": "Quelles sont les complications possibles du dermatofibrosarcome ?\nLe dermatofibrosarcome peut-il se propager ?\nComment gérer une récidive de dermatofibrosarcome ?\nLes cicatrices peuvent-elles poser problème après traitement ?\nY a-t-il des risques psychologiques associés ?", "url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Immunization+Programs&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Dermatofibrosarcome", "description": "Quels sont les facteurs de risque du dermatofibrosarcome ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge influence-t-il le risque de dermatofibrosarcome ?\nLes infections virales sont-elles un facteur de risque ?\nLe sexe influence-t-il le risque de dermatofibrosarcome ?", "url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Immunization+Programs&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on un dermatofibrosarcome ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et une biopsie pour analyse histologique." } }, { "@type": "Question", "name": "Quels examens complémentaires sont nécessaires ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des examens d'imagerie comme l'IRM peuvent être utilisés pour évaluer l'extension tumorale." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent un dermatofibrosarcome ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une lésion cutanée ferme, indolore, souvent pigmentée, qui évolue lentement." } }, { "@type": "Question", "name": "Le dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être confondu avec des lipomes ou d'autres tumeurs cutanées bénignes." } }, { "@type": "Question", "name": "Quel rôle joue l'histopathologie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'histopathologie permet de confirmer la nature maligne de la tumeur et son type histologique." } }, { "@type": "Question", "name": "Quels sont les symptômes d'un dermatofibrosarcome ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent une masse cutanée indolore, souvent avec des bords bien définis." } }, { "@type": "Question", "name": "Le dermatofibrosarcome provoque-t-il des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "En général, il est indolore, mais des douleurs peuvent survenir si la tumeur est compressive." } }, { "@type": "Question", "name": "Peut-on observer des changements de couleur sur la lésion ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la lésion peut présenter des variations de couleur, souvent brunâtre ou violacée." } }, { "@type": "Question", "name": "Les démangeaisons sont-elles fréquentes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les démangeaisons ne sont pas courantes, mais peuvent survenir dans certains cas." } }, { "@type": "Question", "name": "La lésion peut-elle saigner ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La lésion peut saigner, surtout si elle est traumatisée ou si elle est en surface." } }, { "@type": "Question", "name": "Peut-on prévenir le dermatofibrosarcome ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais éviter les traumatismes cutanés peut aider." } }, { "@type": "Question", "name": "Les personnes à risque doivent-elles être surveillées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes ayant des antécédents familiaux ou des lésions cutanées doivent être surveillées." } }, { "@type": "Question", "name": "L'exposition au soleil influence-t-elle le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition excessive au soleil peut augmenter le risque de certains cancers cutanés, mais pas spécifiquement du dermatofibrosarcome." } }, { "@type": "Question", "name": "Des mesures de protection cutanée sont-elles recommandées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, utiliser des écrans solaires et porter des vêtements protecteurs est conseillé." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections liées à des cancers, mais pas spécifiquement le dermatofibrosarcome." } }, { "@type": "Question", "name": "Quel est le traitement principal du dermatofibrosarcome ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est la chirurgie pour enlever complètement la tumeur." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie peut être utilisée en complément après la chirurgie pour réduire le risque de récidive." } }, { "@type": "Question", "name": "Des traitements médicamenteux sont-ils disponibles ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements ciblés peuvent être envisagés dans les cas avancés ou récidivants." } }, { "@type": "Question", "name": "Quelle est l'importance de la surveillance post-opératoire ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance est cruciale pour détecter rapidement toute récidive de la tumeur." } }, { "@type": "Question", "name": "Peut-on traiter le dermatofibrosarcome par chimiothérapie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie n'est généralement pas efficace pour le dermatofibrosarcome, sauf cas avancés." } }, { "@type": "Question", "name": "Quelles sont les complications possibles du dermatofibrosarcome ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la récidive locale et, dans de rares cas, des métastases." } }, { "@type": "Question", "name": "Le dermatofibrosarcome peut-il se propager ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Il a un faible potentiel de métastase, mais peut envahir les tissus voisins." } }, { "@type": "Question", "name": "Comment gérer une récidive de dermatofibrosarcome ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La récidive nécessite souvent une nouvelle intervention chirurgicale et un suivi étroit." } }, { "@type": "Question", "name": "Les cicatrices peuvent-elles poser problème après traitement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cicatrices peuvent être inesthétiques et nécessiter des soins ou des interventions esthétiques." } }, { "@type": "Question", "name": "Y a-t-il des risques psychologiques associés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic et le traitement peuvent entraîner du stress et de l'anxiété chez les patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du dermatofibrosarcome ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents de traumatismes cutanés, des maladies génétiques et l'exposition à des radiations." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de dermatofibrosarcome peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de dermatofibrosarcome ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le dermatofibrosarcome est plus fréquent chez les adultes jeunes, généralement entre 20 et 50 ans." } }, { "@type": "Question", "name": "Les infections virales sont-elles un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus de l'herpès, peuvent être associées à un risque accru." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque de dermatofibrosarcome ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de différence significative entre les sexes concernant le risque de dermatofibrosarcome." } } ] } ] }

Sources (10000 au total)

Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.

Pakistan has a well-established Expanded Program on Immunization (EPI) however vaccine-preventable diseases still account for high infant and child mortality rates. This study describes the differenti... From October 2014 to September 2018, we enrolled children younger than 2 years of age from the Matiari Demographic Surveillance System in Sindh, Pakistan. Socio-demographic and vaccination history wer... Of the 3140 enrolled children, 48.4 % received all EPI recommended vaccines. Only 21.2 % of these were age appropriate. Around 45.4 % of the children were partially vaccinated, and 6.2 % were unvaccin... Vaccine coverage was low among children in Matiari, Pakistan, and majority received delayed doses. Parents' education status and year of study enrollment was protective against vaccine dropout and del...

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.

In response to the substantial clinical and economic burden of diseases caused by... A Markov model that simulated the disease processes of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) over a newborn cohort lifetime was used to evaluate the cost-effecti... Vaccination with PHiD-CV or PCV13 was estimated to avert approximately 700 cases of IPD (200 meningitis, 500 bacteremia), and around 5,000 cases of all-cause pneumonia. However, PHiD-CV vaccination wa... PCVs are a cost-effective strategy to relieve the burden associated with diseases caused by...

The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon's Expanded program on Immunization.

Immunization is regarded as one of the most cost-effective public health interventions in global health. However, its cost-effectiveness depends greatly on the knowledge and skills of vaccinators. Wit... Through a descriptive cross-sectional design, we used structured questionnaires and observation guides to collect data from vaccination staff in health facilities that were selected by a multistage sa... Overall, we collected data from Expanded Program on Immunization focal staff in 265 health facilities across 68 health districts. Over half (53%) of the surveyed facilities were found in rural areas. ... This study suggests marked deficits in immunization knowledge among vaccination staff and exposes common attitudes and practices that could contribute to missed opportunities for vaccination and hinde...

Analyzing the usage of theories of change for routine immunization programs -- a review of impact evaluations from LMICs.

In this article we analyzed the extent of the usage of Theories of Change (TOCs) and causal pathways in the evaluation of immunization programs to identify the challenges to generating evidence on how... We analyzed the use of the TOC in impact evaluations (IEs) of immunization interventions published after 2010, and its associated articles. The review includes studies from Evidence Gap Map and Yale r... Our review included 47 large-scale and 45 small-to medium-scale interventions. Of the included studies, 19% used a TOC, 56% described a causal pathway or used a conceptual diagram with varying degrees... Future implementers and evaluators need to develop clear TOCs that are based on established theory and have clearly articulated the underlying assumptions. Large-scale health system strengthening init...

Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018).

Rotavirus (RV) vaccination was included in the Finnish National immunization Program (NIP) in 2009. RotaTeq (RV5) has been used exclusively with a national average vaccination coverage rate (VCR) of >... We first describe the incidence of RVGE, viral gastroenteritis (VGE), and acute gastroenteritis (AGE) for all Finnish children born during 2008-2011. Children were stratified by the year of birth into... RVGE incidence decreased significantly soon after implementation of RV vaccination in the NIP. In vaccine-eligible cohorts, no clear peak incidence in the youngest age groups could be observed, and no... Incidence of RVGE has remained low in all age groups during the 10 years following introduction of RV vaccine in the Finnish NIP. Differences in RVGE incidence were observed in regions with high as co...

Comprehensive assessment of the implementation of maternal immunization programs in Italy: A national survey across maternity care units.

The authors aimed to assess the characteristics and integration of immunization services into the prenatal care provided by maternity care units (MCUs) in Italy.... A cross-sectional nationwide study using a web-based survey was conducted from June to August 2021. The study population consisted of 342 obstetricians/gynecologists (OB/GYNs), members of the Italian ... Overall, 112 of 342 MCUs completed the survey, for an overall response rate of 32.7%. Almost all MCUs (96.4%) provided vaccine information, but only 22% had an onsite vaccination clinic. Less than hal... Institutional barriers and lack of certain vaccine-related services offered during prenatal care in Italian MCUs might be responsible for many missed vaccination opportunities. Embedding maternal immu...

Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe.

Delaying of policies for immunization of aging adults, low vaccine uptake, and the lack of supportive evidence at the national level could diminish the value in health and economics of such programs. ... The tool was developed in two phases. First, a modified Delphi process was used to construct the tool. The process included a literature review, stakeholder consultations, and a three-round Delphi stu... The review identified 16 tools and frameworks that formed the first version of our tool with 14 items. Eight experts were involved in the Delphi panel. Through three Delphi rounds, four items were add... Through a thorough and transparent process, a country score tool was developed helping to identify strengths, weaknesses, and evidential requirements for decision-making and implementation of immuniza...